|
|
|
| Effect of Levetiracetam on epilepsy in children and its effect on cognitive function |
| XING Hongyu1 LIU Pisong2 YANG Yihai3 HAN Hong4 |
1.Department of Pediatrics, Shanxi Medical University, Shanxi Province, Taiyuan 030001, China;
2.Department of Pediatric Intensive Care Medicine, the First People′s Hospital of Datong, Shanxi Province, Datong 037000, China;
3.Department of Seven Pediatrics, the First People′s Hospital of Datong, Shanxi Province, Datong 037000, China;
4.Department of Neurology, Children′s Hospital Shanxi, Shanxi Province, Taiyuan 030001, China |
|
|
|
Abstract Objective To investigate the efficacy and safety of Levetiracetam in the treatment of epilepsy in children and its effect on cognitive function. Methods From February 2018 to January 2019, 96 pediatric epilepsy patients admitted to the Outpatient Department of Pediatrics and Neurology of Shanxi Children′s Hospital were selected as the study objects. According to the random number table method, the patients were divided into the observation group and the control group, each group with 48 cases. The observation group was given Levethracetam Tablets orally alone, the control group was given Oxazepine in combination on this basis. Both groups were treated for 16 weeks. Clinical efficacy, improvement of EEG before and after treatment, and occurrence of adverse reactions during treatment were compared between the two groups, and cognitive function of the children were evaluated. Results After 16 weeks of intervention, there was no statistically significant difference in clinical efficacy and EEG efficacy between two groups (P ＞ 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P ＜ 0.05). Operational intelligence quotient (PIQ), verbal intelligence quotient (VIQ), and full intelligence quotient (FIQ) scores of the two groups were all increased after treatment (all P ＜ 0.05). After treatment, FIQ score of the observation group was lower that of the control group (P ＜ 0.05). There was no significant difference in PIQ and VIQ between the two groups after treatment (P ＞ 0.05). Conclusion The treatment effect of Levetiracetam alone in children with epilepsy is equivalent to that of Ocasepine, which can effectively improve the clinical symptoms, enhance the cognitive function of children, reduce the incidence of adverse reactions, and is relatively safe.
|
|
|
|
|
|
[1] Russ SA，Larson K，Halfon N. A national profile of childhood epilepsy and seizure disorder [J]. Pediatrics，2012， 129（2）：256-264.
[2] Liu X，Carney PR，Bussing R，et al. Trends in antiepileptic drug use in children and adolescents with epilepsy [J]. Pediatr Neurol，2017，74：32-40.
[3] Weijenberg A，Brouwer OF，Callenbach PM. Levetiracetam monotherapy in children with epilepsy：a systematic review [J]. CNS Drugs，2015，29（5）：371-382.
[4] 杨圣海，王珺，王立文，等.癫痫儿童抗癫痫药使用情况及超说明书用药的调查分析[J].中国医药导报，2018，15（11）：45-48.
[5] 陈海燕，冉志玲.左乙拉西坦对小儿癫痫合并智力低下治疗的影响[J].基因组学与应用生物学，2019，38（2）：928-932.
[6] Kim JS，Lee JH，Ryu HW，et al. Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus [J]. Pediatr Emerg Care，2014，30（8）：525-528.
[7] Lynch BA，Lambeng N，Nocka K，et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam [J]. Proc Natl Acad Sci U S A，2004， 101（26）：9861-9866.
[8] 王书玲，侯江红，陈团营，等.定痫丸加减联合左乙拉西坦治疗小儿癫痫痰火扰神证疗效及对认知功能、生活质量的影响[J].中国实验方剂学杂志，2018，24（23）：171-176.
[9] Muramatsu K，Sawaura N，Ogata T，et al. Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy [J]. Brain Dev，2017，39（3）：231-235.
[10] 刘楠，朱建萍，张胜，等.左乙拉西坦对癫痫患儿骨代谢影响的临床研究[J].中国医学创新，2018，15（1）：30-33.
[11] Patsalos PN. Clinical pharmacokinetics of levetiracetam [J]. Clin Pharmacokinet，2004，43（11）：707-724.
[12] Kartal A. Can high-dose levetiracetam be safe? A case report of prolonged accidental high-dose levetiracetam administration and review of the literature [J]. Clin Neuropharmacol，2017，40（5）：217-218.
[13] Ozkale Y，Ozkale M，Saygi S，et al. Long-term accidental overdose of levetiracetam in an infant [J]. J Child Neurol，2014，29（7）：959-961.
[14] Bodmer M，Monte AA，Kokko J，et al. Safety of non-therapeutic levetiracetam ingestions--a poison center based study [J]. Pharmacoepidemiol Drug Saf，2011，20（4）：366-369.
[15] Lewis JC，Albertson TE，Walsh MJ. An 11-year review of levetiracetam ingestions in children less than 6 years of age [J]. Clin Toxicol （Phila），2014，52（9）：964-968.
[16] Mbizvo GK，Dixon P，Hutton JL，et al. The adverse effects profile of levetiracetam in epilepsy：a more detailed look[J]. Int J Neurosci，2014，124（9）：627-634.
[17] Egunsola O，Choonara I，Sammons HM，et al. Safety of antiepileptic drugs in children and young people：A prospective cohort study [J]. Seizure，2018，56：20-25.
[18] Arican P，Gencpinar P，Cavusoglu D，et al. Levetiracetam monotherapy for the treatment of infants with epilepsy[J]. Seizure，2018，56：73-77.
[19] Sim GY，Kim WS. Levetiracetam monotherapy in children with epilepsy [J]. Korean Child Neurol Soc，2011， 19：26-32.
[20] Egunsola O，Choonara I，Sammons HM. Safety of levetiracetam in paediatrics：a systematic review [J]. PLoS One，2016，11（3）：e0149686. |
|
|
|
